Jeffrey S. Glenn is Director at Eiger BioPharmaceuticals, Inc. (EIGR). They have made 5 open-market trades across 1 company since 2016, most recently 2022-12-22.
CIK 0001670382
5 open-market purchases totalling $733K since 2016, never a sale. Across 5 scored buys the stock is up 17.0% at ninety days, and 6.3 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| EIGR | 182,355 | $315K |
Shares reported on the most recent Form 4, priced at the 2022-12-27 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 60% | 40% |
| Avg Move | +8.8% | +15.6% | +17.0% |
| Alpha | +6.5% | +9.8% | +6.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EIGR | BUY | 2022-12-22 | 2022-12-27 | $1.28 | $128K | +10.3% | +30.8% | -5.6% |
| EIGR | BUY | 2020-08-11 | 2020-08-12 | $11.46 | $115K | +1.4% | -12.5% | -13.3% |
| EIGR | BUY | 2020-03-16 | 2020-03-17 | $5.03 | $151K | +27.4% | +42.7% | +96.0% |
| EIGR | BUY | 2017-09-01 | 2017-09-05 | $9.53 | $143K | +14.9% | +28.4% | +21.6% |
| EIGR | BUY | 2016-11-17 | 2016-11-21 | $12.74 | $197K | -10.0% | -11.2% | -13.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.